Navigation Links
Press registration is now open for EULAR 2011, May 25-28, London
Date:2/28/2011

Press registration is free of charge for all holders of a valid press card / formal journalist credentials. Press will have access to the onsite press facilities, including a working room and an interview room. The Press Office staff will also be able to assist you in organising interviews with relevant experts.

EULAR is one of the foremost international medical meetings in rheumatology and receives an attendance of over 12,000 delegates and 300 members of the press each year. The congress will cover the full spectrum of the rheumatic diseases, from new data to basic science, clinical symposia, abstract sessions, presentation and discussion of difficult cases, workshops, special interest group sessions and state-of-the-art lectures.

Press materials will select key newsworthy stories, from new clinical trial data to the social issues associated with rheumatologic conditions, along with specific stories on paediatric rheumatology. Several press conferences will be held during EULAR timings to be confirmed.

We look forward to seeing you at EULAR 2011 in London.


'/>"/>

Contact: Rory Berrie
rory.berrie@cohnwolfe.com
44-207-331-5317
European League Against Rheumatism
Source:Eurekalert

Page: 1

Related biology news :

1. European Multidisciplinary Conference in Thoracic Oncology -- press program
2. Press registration open for clinical nutrition conference
3. Groundbreaking technology will revolutionize blood pressure measurement
4. Media alert: ACMG 2011 Clinical Genetics Meeting -- press registration is now open
5. Cell Press wins prestigious PROSE Award for Article of the Future
6. A second pathway for antidepressants
7. Scientific research reveals brain alterations linking omega 3 deficit with depression
8. New clue to lupus: Failed autoimmune suppression mechanism
9. A deficiency of dietary omega-3 may explain depressive behaviors
10. Common antibiotics and blood pressure medication may result in hospitalization
11. MicroRNA suppresses prostate cancer stem cells and metastasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/12/2017)... , Jan. 12, 2017  New research undertaken by ... office of the future.  1,000 participants were simply asked which ... months which we may consider standard issue.  Insights on what ... 2017 were also gathered from futurists and industry leaders including ... James Canton .  Some of ...
(Date:1/6/2017)... BOULDER, Colo. , Jan. 5, 2017 /PRNewswire/ ... join the "Digital Life Alliance" established by iCarbonX, ... in 2015 to build a "Global Digital Health ... based on a combination of individual,s biological, behavioral ... Under the agreement between the companies, SomaLogic will ...
(Date:12/22/2016)... , Dec. 20, 2016  As part of its longstanding ... leading personal genetics company, recently released its latest children,s book, ... The book focuses on the topics of inheritance and variation ... Standards (NGSS) taught in elementary school classrooms in the US. ... series by illustrator Ariana Killoran , whose previous book ...
Breaking Biology News(10 mins):
(Date:1/20/2017)... , January 20, 2017 ... is one of leading causes of death worldwide. There ... the number of cancer related deaths increased gradually over ... in incidence rate of various cancers continues to drive ... research report by Global Market Insights, Inc. cancer biological ...
(Date:1/19/2017)... PUNE, India , Jan. 19, 2017  Market Research Future ... The Global Market for Liquid Biopsy is growing rapidly and expected ... period. Market Highlights ... The Global Liquid Biopsy Market has been assessed as ... high growth figures and boom in the coming future. There has ...
(Date:1/19/2017)... Jan 19, 2017 Research and Markets ... has announced the addition of the ... - Forecast to 2025" report to their offering. ... The report provides a detailed analysis on current and future market ... 2025, using estimated market values as the base numbers ...
(Date:1/19/2017)... ANNAPOLIS, Md. and GAITHERSBURG, ... Inc. (NYSE MKT: PIP) and Altimmune, Inc., a ... the signing of a definitive agreement for the ... transaction. Altimmune,s current investors include Novartis Venture Fund, ... company will be a fully-integrated and diversified immunotherapeutics ...
Breaking Biology Technology: